Comparing the current results to its competitors, Mineralys Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.98 %, recorded in the same quarter.
Mineralys Therapeutics Inc , slower than the average decrease reported by the company's competitors of -84.53 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -84.53 %
Mineralys Therapeutics Inc 's Comment on Competition and Industry Peers
The biopharmaceutical industry is characterized by intense competition and rapid technological advancements, with a focus on proprietary products. Lorundrostat, if approved, will enter multiple markets, particularly for hypertension. Competitors include existing and emerging therapies from pharmaceutical, biopharmaceutical, biotechnology, and therapeutics companies, as well as universities and research institutions. These competitors may possess greater resources and expertise. Competition is categorized into three groups, including companies developing angiotensin system inhibitors (ASIs) such as AstraZeneca, Boehringer Ingelheim, Damian Pharma, and CORXEL.
August 5, 2024
Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results RADNOR, Pa. Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for hypertension, chronic kidney disease (CKD), and other conditions driven by dysregulated aldosterone, has announced that it will release its financial results for the second quarter of 2024 on Tuesday, August 13, 2024. This announcement will occur after the financial markets have closed for the day.The company has scheduled a conference call to discuss the financial results. This event will presumably address the company s progress in its clinical stage endeavors, including developments i...
Publicly Traded Peers of Mineralys Therapeutics Inc
Adagene Inc Share Performance
+79.89%
This Year
Adagene Inc
Profile
Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.
Sources:
Mineralys Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Mineralys Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
